Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

Also called NCT02081599

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 148 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02081599
Other papers using this trial's data
  • Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period Expert opinion on pharmacotherapy, 2017-09 DOI, PubMed 28741385

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02081599. Randomized; quadruple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2017-01-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneli (Teneligliptin)
Intervention (Drug)
Placebo
Intervention (Drug)
Insulin
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02081599
Content hash
9b55ecf83c4bd771211a6331a9b3e9a168428338d7e132e1d9036c7991a23254